<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2fb0b7eb-a069-d126-e063-6294a90a5c59"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">Hydrocortisone Tablets USP</content>
      <br/>
      <content styleCode="bold">8458201/0325F</content>
      <br/>
      <content styleCode="bold">Rx only</content>
   </title>
   <effectiveTime value="20250407"/>
   <setId root="506aab0d-9308-4d60-90b3-7d64952fff36"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="929561009"/>
            <name>American Health Packaging</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="929561009"/>
                        <name>American Health Packaging</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="repack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60687-582" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="325e6307-893c-bc6a-e063-6394a90a1bdc"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250407"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60687-582" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Hydrocortisone</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Hydrocortisone</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="64380-971" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="WI4X0X7BPJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCORTISONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="WI4X0X7BPJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYDROCORTISONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="60687-582-11" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="100" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="60687-582-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43179" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX, UNIT-DOSE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20210401"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA207029" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210401"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText>to off White</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText>OVAL</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">H;10</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID1">
               <id root="2fb0b7eb-a06a-d126-e063-6294a90a5c59"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Hydrocortisone tablets, USP contain hydrocortisone which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Hydrocortisone USP is white to practically white, odorless, crystalline powder with a melting point of about 215º C. It is very slightly soluble in water and in ether; sparingly soluble in acetone and in alcohol; slightly soluble in chloroform.</paragraph>
                  <paragraph>The chemical name for hydrocortisone is pregn-4-ene-3,20-dione,11,17,21-trihydroxy-, (11β)-. Its molecular weight is 362.46 and the structural formula is as outlined below.</paragraph>
                  <renderMultiMedia ID="id356" referencedObject="ID_8d3564b1-11ff-4744-85be-3d035e2e0033"/>
                  <paragraph>Hydrocortisone tablets, USP are available for oral administration in three strengths: each tablet contains either 5 mg, 10 mg, or 20 mg of hydrocortisone. Inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate and microcrystalline cellulose.</paragraph>
               </text>
               <effectiveTime value="20250204"/>
               <component>
                  <observationMedia ID="ID_8d3564b1-11ff-4744-85be-3d035e2e0033">
                     <text>Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID5">
               <id root="2fb0b7eb-a06b-d126-e063-6294a90a5c59"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>ACTIONS</title>
               <text>
                  <paragraph>Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.</paragraph>
                  <paragraph>Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.</paragraph>
               </text>
               <effectiveTime value="20250204"/>
            </section>
         </component>
         <component>
            <section ID="ID7">
               <id root="2fb0b7eb-a06c-d126-e063-6294a90a5c59"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Hydrocortisone tablets are indicated in the following conditions.</paragraph>
               </text>
               <effectiveTime value="20250204"/>
               <component>
                  <section ID="ID9">
                     <id root="2fb0b7eb-a06d-d126-e063-6294a90a5c59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1. Endocrine Disorders</title>
                     <text>
                        <paragraph>Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance)</paragraph>
                        <paragraph>Congenital adrenal hyperplasia 
  <br/>  Non suppurative thyroiditis 
  <br/>  Hypercalcemia associated with cancer
 </paragraph>
                     </text>
                     <effectiveTime value="20250204"/>
                  </section>
               </component>
               <component>
                  <section ID="ID11">
                     <id root="2fb0b7eb-a06e-d126-e063-6294a90a5c59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2. Rheumatic Disorders</title>
                     <text>
                        <paragraph>As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:</paragraph>
                        <paragraph>Psoriatic arthritis 
  <br/>  Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) 
  <br/>  Ankylosing spondylitis 
  <br/>  Acute and subacute bursitis 
  <br/>  Acute nonspecific tenosynovitis 
  <br/>  Acute gouty arthritis 
  <br/>  Post-traumatic osteoarthritis 
  <br/>  Synovitis of osteoarthritis 
  <br/>  Epicondylitis
 </paragraph>
                     </text>
                     <effectiveTime value="20250204"/>
                  </section>
               </component>
               <component>
                  <section ID="ID14">
                     <id root="2fb0b7eb-a06f-d126-e063-6294a90a5c59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>3. Collagen Diseases</title>
                     <text>
                        <paragraph>During an exacerbation or as maintenance therapy in selected cases of:</paragraph>
                        <paragraph>Systemic lupus erythematosus 
  <br/>  Systemic dermatomyositis (polymyositis) 
  <br/>  Acute rheumatic carditis
 </paragraph>
                     </text>
                     <effectiveTime value="20250204"/>
                  </section>
               </component>
               <component>
                  <section ID="ID17">
                     <id root="2fb0b7eb-a070-d126-e063-6294a90a5c59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4. Dermatologic Diseases</title>
                     <text>
                        <paragraph>Pemphigus 
  <br/>  Bullous dermatitis herpetiformis 
  <br/>  Severe erythema multiforme (Stevens-Johnson syndrome) 
  <br/>  Exfoliative dermatitis 
  <br/>  Mycosis fungoides 
  <br/>  Severe psoriasis 
  <br/>  Severe seborrheic dermatitis
 </paragraph>
                     </text>
                     <effectiveTime value="20250204"/>
                  </section>
               </component>
               <component>
                  <section ID="ID19">
                     <id root="2fb0b7eb-a071-d126-e063-6294a90a5c59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5. Allergic States</title>
                     <text>
                        <paragraph>Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:</paragraph>
                        <paragraph>Seasonal or perennial allergic rhinitis 
  <br/>  Serum sickness 
  <br/>  Bronchial asthma 
  <br/>  Contact dermatitis 
  <br/>  Atopic dermatitis 
  <br/>  Drug hypersensitivity reactions
 </paragraph>
                     </text>
                     <effectiveTime value="20250204"/>
                  </section>
               </component>
               <component>
                  <section ID="ID22">
                     <id root="2fb0b7eb-a072-d126-e063-6294a90a5c59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6. Ophthalmic Diseases</title>
                     <text>
                        <paragraph>Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:</paragraph>
                        <paragraph>Allergic conjunctivitis 
  <br/>  Keratitis 
  <br/>  Allergic corneal marginal ulcers 
  <br/>  Herpes zoster ophthalmicus 
  <br/>  Iritis and iridocyclitis 
  <br/>  Chorioretinitis 
  <br/>  Anterior segment inflammation 
  <br/>  Diffuse posterior uveitis and choroiditis 
  <br/>  Optic neuritis 
  <br/>  Sympathetic ophthalmia
 </paragraph>
                     </text>
                     <effectiveTime value="20250204"/>
                  </section>
               </component>
               <component>
                  <section ID="ID25">
                     <id root="2fb0b7eb-a073-d126-e063-6294a90a5c59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7. Respiratory Diseases</title>
                     <text>
                        <paragraph>Symptomatic sarcoidosis 
  <br/>  Loeffler's syndrome not manageable by other means 
  <br/>  Berylliosis 
  <br/>  Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy 
  <br/>  Aspiration pneumonitis
 </paragraph>
                     </text>
                     <effectiveTime value="20250204"/>
                  </section>
               </component>
               <component>
                  <section ID="ID27">
                     <id root="2fb0b7eb-a074-d126-e063-6294a90a5c59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8. Hematologic Disorders</title>
                     <text>
                        <paragraph>Idiopathic thrombocytopenic purpura in adults 
  <br/>  Secondary thrombocytopenia in adults 
  <br/>  Acquired (autoimmune) hemolytic anemia 
  <br/>  Erythroblastopenia (RBC anemia) 
  <br/>  Congenital (erythroid) hypoplastic anemia
 </paragraph>
                     </text>
                     <effectiveTime value="20250204"/>
                  </section>
               </component>
               <component>
                  <section ID="ID29">
                     <id root="2fb0b7eb-a075-d126-e063-6294a90a5c59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>9. Neoplastic Diseases</title>
                     <text>
                        <paragraph>For palliative management of:</paragraph>
                        <paragraph>Leukemias and lymphomas in adults 
  <br/>  Acute leukemia of childhood
 </paragraph>
                     </text>
                     <effectiveTime value="20250204"/>
                  </section>
               </component>
               <component>
                  <section ID="ID32">
                     <id root="2fb0b7eb-a076-d126-e063-6294a90a5c59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10. Edematous States</title>
                     <text>
                        <paragraph>To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.</paragraph>
                     </text>
                     <effectiveTime value="20250204"/>
                  </section>
               </component>
               <component>
                  <section ID="ID34">
                     <id root="2fb0b7eb-a077-d126-e063-6294a90a5c59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>11. Gastrointestinal Diseases</title>
                     <text>
                        <paragraph>To tide the patient over a critical period of the disease in:</paragraph>
                        <paragraph>Ulcerative colitis 
  <br/>  Regional enteritis
 </paragraph>
                     </text>
                     <effectiveTime value="20250204"/>
                  </section>
               </component>
               <component>
                  <section ID="ID37">
                     <id root="2fb0b7eb-a078-d126-e063-6294a90a5c59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12. Miscellaneous</title>
                     <text>
                        <paragraph>Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy 
  <br/>  Trichinosis with neurologic or myocardial involvement
 </paragraph>
                     </text>
                     <effectiveTime value="20250204"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID39">
               <id root="2fb0b7eb-a079-d126-e063-6294a90a5c59"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Systemic fungal infections and known hypersensitivity to components</paragraph>
               </text>
               <effectiveTime value="20250204"/>
            </section>
         </component>
         <component>
            <section ID="ID41">
               <id root="3236a943-9a62-3d60-e063-6394a90af15a"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Immunosuppression and Increased Risk of Infection</content>
                     <br/>
Corticosteroids, including hydrocortisone, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can:
 </paragraph>
                  <list listType="unordered">
                     <item>Reduce resistance to new infections</item>
                     <item>Exacerbate existing infections</item>
                     <item>Increase the risk of disseminated infections</item>
                     <item>Increase the risk of reactivation or exacerbation of latent infections</item>
                     <item>Mask some signs of infection</item>
                  </list>
                  <paragraph>Corticosteroid-associated infections can be mild but can be severe and at times fatal. The rate of infectious complications increases with increasing corticosteroid dosages.</paragraph>
                  <paragraph>Monitor for the development of infection and consider hydrocortisone withdrawal or dosage reduction as needed.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Tuberculosis</content>
                     <br/>
If hydrocortisone is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur. Closely monitor such patients for reactivation. During prolonged hydrocortisone therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis.
 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Varicella Zoster and Measles Viral Infections</content>
                     <br/>
Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including hydrocortisone. In corticosteroid-treated patients who have not had these diseases or are non-immune, particular care should be taken to avoid exposure to varicella and measles:
 </paragraph>
                  <list listType="unordered">
                     <item>If a hydrocortisone-treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin may be indicated. If varicella develops, treatment with antiviral agents may be considered.</item>
                     <item>If a hydrocortisone-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated.</item>
                  </list>
                  <paragraph>
                     <content styleCode="italics">Hepatitis B Virus Reactivation</content>
                     <br/>
Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including hydrocortisone. Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection.
 </paragraph>
                  <paragraph>Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with hydrocortisone. For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Fungal Infections</content>
                     <br/>
Corticosteroids, including hydrocortisone, may exacerbate systemic fungal infections; therefore, avoid hydrocortisone use in the presence of such infections unless hydrocortisone is needed to control drug reactions. For patients on chronic hydrocortisone therapy who develop systemic fungal infections, hydrocortisone withdrawal or dosage reduction is recommended.
 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Amebiasis</content>
                     <br/>
Corticosteroids, including hydrocortisone, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating hydrocortisone in patients who have spent time in the tropics or patients with unexplained diarrhea.
 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Strongyloides Infestation</content>
                     <br/>
Corticosteroids, including hydrocortisone, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.
 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Cerebral Malaria</content>
                     <br/>
Avoid corticosteroids, including hydrocortisone, in patients with cerebral malaria.
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Ophthalmic Effects</content>
                     <br/>
Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Kaposi's Sarcoma</content>
                     <br/>
Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement of Kaposi's sarcoma.
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Hypertension, Volume Overload, and Hypokalemia</content>
                     <br/>
Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Vaccinations</content>
                     <br/>
Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered to patients receiving immunosuppressive doses of corticosteroids; however, the response to such vaccines may be diminished. Indicated immunization procedures may be undertaken in patients receiving nonimmunosuppressive doses of corticosteroids.
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Usage in Pregnancy</content>
                     <br/>
Since adequate human reproduction studies have not been done with corticosteroids, the use of these drugs in pregnancy, nursing mothers or women of child bearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy, should be carefully observed for signs of hypoadrenalism.
 </paragraph>
                  <paragraph>Corticosteroids have been shown to impair fertility in male rats.</paragraph>
               </text>
               <effectiveTime value="20250204"/>
            </section>
         </component>
         <component>
            <section ID="ID43">
               <id root="2fb0b7eb-a07b-d126-e063-6294a90a5c59"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20250204"/>
               <component>
                  <section ID="ID44">
                     <id root="3236c989-7fd7-4e2c-e063-6394a90a9d56"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General Precautions</title>
                     <text>
                        <paragraph>Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted.</paragraph>
                        <paragraph>There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis.</paragraph>
                        <paragraph>Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.</paragraph>
                        <paragraph>The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.</paragraph>
                        <paragraph>Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.</paragraph>
                        <paragraph>Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis.</paragraph>
                        <paragraph>Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.</paragraph>
                        <paragraph>Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.</paragraph>
                        <paragraph>Pheochromocytoma crisis, which can be fatal, has been reported after administration of systemic corticosteroids. In patients with suspected pheochromocytoma, consider the risk of pheochromocytoma crisis prior to administering corticosteroids.</paragraph>
                        <paragraph>In post marketing experience, tumor lysis syndrome (TLS) has been reported in patients with malignancies, including hematological malignancies and solid tumors, following the use of systemic corticosteroids alone or in combination with other chemotherapeutic agents. Patients at high risk of TLS, such as patients with tumors that have a high proliferative rate, high tumor burden and high sensitivity to cytotoxic agents, should be monitored closely and appropriate precautions should be taken.</paragraph>
                     </text>
                     <effectiveTime value="20250204"/>
                  </section>
               </component>
               <component>
                  <section ID="ID46">
                     <id root="2fb0b7eb-a07d-d126-e063-6294a90a5c59"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <text>
                        <paragraph>The pharmacokinetic interactions listed below are potentially clinically important. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. Therefore, the dose of corticosteroid should be titrated to avoid steroid toxicity. Corticosteroids may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. The effect of corticosteroids on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.</paragraph>
                     </text>
                     <effectiveTime value="20250204"/>
                  </section>
               </component>
               <component>
                  <section ID="ID48">
                     <id root="2fb0b7eb-a07e-d126-e063-6294a90a5c59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Information for the Patient</title>
                     <text>
                        <paragraph>Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chicken pox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.</paragraph>
                     </text>
                     <effectiveTime value="20250204"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID50">
               <id root="2fb0b7eb-a07f-d126-e063-6294a90a5c59"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Fluid and Electrolyte Disturbances</content>
                     <br/>  Sodium retention 
  <br/>  Fluid retention 
  <br/>  Congestive heart failure in susceptible patients 
  <br/>  Potassium loss 
  <br/>  Hypokalemic alkalosis 
  <br/>  Hypertension

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Musculoskeletal</content>
                     <br/>  Muscle weakness 
  <br/>  Steroid myopathy 
  <br/>  Loss of muscle mass 
  <br/>  Osteoporosis 
  <br/>  Tendon rupture, particularly of the Achilles tendon 
  <br/>  Vertebral compression fractures 
  <br/>  Aseptic necrosis of femoral and humeral heads 
  <br/>  Pathologic fracture of long bones

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Gastrointestinal</content>
                     <br/>  Peptic ulcer with possible perforation and hemorrhage 
  <br/>  Pancreatitis 
  <br/>  Abdominal distention 
  <br/>  Ulcerative esophagitis 
  <br/>  Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT) and alkaline phosphatase have been observed following corticosteroid treatment. These changes are usually small, not associated with any clinical syndrome and are reversible upon discontinuation.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dermatologic</content>
                     <br/>  Impaired wound healing 
  <br/>  Thin fragile skin 
  <br/>  Petechiae and ecchymoses 
  <br/>  Facial erythema 
  <br/>  Increased sweating 
  <br/>  May suppress reactions to skin tests

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Neurological</content>
                     <br/>  Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment 
  <br/>  Convulsions 
  <br/>  Vertigo 
  <br/>  Headache 
  <br/>  Epidural lipomatosis

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Endocrine</content>
                     <br/>  Development of Cushingoid state 
  <br/>  Suppression of growth in children 
  <br/>  Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness 
  <br/>  Menstrual irregularities 
  <br/>  Decreased carbohydrate tolerance 
  <br/>  Manifestations of latent diabetes mellitus 
  <br/>  Increased requirements for insulin or oral hypoglycemic agents in diabetics

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Ophthalmic</content>
                     <br/>  Central serous chorioretinopathy 
  <br/>  Posterior subcapsular cataracts 
  <br/>  Increased intraocular pressure 
  <br/>  Glaucoma 
  <br/>  Exophthalmos

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Metabolic</content>
                     <br/>  Negative nitrogen balance due to protein catabolism

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Blood and lymphatic system disorders</content>
                     <br/>  Leukocytosis

 </paragraph>
               </text>
               <effectiveTime value="20250204"/>
            </section>
         </component>
         <component>
            <section ID="ID52">
               <id root="3236d01a-5564-ccd9-e063-6294a90afcf7"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>The initial dosage of hydrocortisone tablets may vary from 20 mg to 240 mg of hydrocortisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, hydrocortisone should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of hydrocortisone for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually, rather than abruptly.</paragraph>
               </text>
               <effectiveTime value="20250204"/>
            </section>
         </component>
         <component>
            <section ID="ID54">
               <id root="2fb16781-4802-53c3-e063-6294a90a20f3"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Hydrocortisone tablets, USP are available in the following strengths and package sizes:</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">5 mg</content>
                     </content>
                     <br/>
White to off-white oval tablets debossed on one side with a bisect and other side with "H5".
  <br/>
Unit dose packages of 30 (3 x 10) NDC 60687-844-21
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">10 mg</content>
                     </content>
                     <br/>
White to off-white oval tablets debossed on one side with a bisect and other side with "H10".
  <br/>
Unit dose packages of 100 (10 x 10) NDC 60687-582-01
 </paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].</paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR YOUR PROTECTION: </content>Do not use if blister is torn or broken.
 </paragraph>
               </text>
               <effectiveTime value="20250204"/>
            </section>
         </component>
         <component>
            <section ID="ID56">
               <id root="2fb0b7eb-a082-d126-e063-6294a90a5c59"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>REFERENCES</title>
               <text>
                  <list listType="ordered">
                     <item>Fekety R. Infections associated with corticosteroids and immunosuppressive therapy. In: Gorbach SL, Bartlett JG, Blacklow NR, eds.
  
   <content styleCode="italics">Infectious Diseases</content>. Philadelphia: WB Saunders Company 1992:1050-1.
 
  </item>
                     <item>Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticoids.
  
   <content styleCode="italics">Rev Infect Dis</content>1989:11(6):954-63.
 
  </item>
                  </list>
               </text>
               <effectiveTime value="20250204"/>
            </section>
         </component>
         <component>
            <section ID="ID_fbeff810-08fb-4a56-a737-7d2fd3d7f726">
               <id root="32368938-e94e-8c73-e063-6294a90a477e"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>PACKAGING INFORMATION</title>
               <text>
                  <paragraph>American Health Packaging unit dose blisters (see 
  <linkHtml href="#ID54">How Supplied</linkHtml> section) contain drug product from Strides Pharma Inc. as follows:
  <br/>
(5 mg / 30 UD) NDC 60687-844-21 packaged from NDC 64380-970
  <br/>
(10 mg / 100 UD) NDC 60687-582-01 packaged from NDC 64380-971
 </paragraph>
                  <paragraph>Distributed by:
  <br/>
                     <content styleCode="bold">American Health Packaging</content>
                     <br/>
Columbus, OH 43217
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">8458201/0325F</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250204"/>
            </section>
         </component>
         <component>
            <section ID="ID_f897c336-b59f-43be-aae3-2ce49808c4e9">
               <id root="30b46791-e398-8ea4-e063-6394a90a9a04"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel - Carton - 10 mg</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_1d4dbee1-4b55-4ee9-e063-6394a90ad57b"/>
                  </paragraph>
                  <paragraph>NDC 60687-
  <content styleCode="bold">582</content>-01
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Hydrocortisone</content>
                     <br/>
Tablets, USP
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">10 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 Tablets (10 x 10)               Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Each Tablet Contains:</content>
                     <br/>
Hydrocortisone..........................................................................10 mg
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Usual Dosage: </content>See full prescribing information.
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Warning - </content>This potent drug must be used only under the direct
  <br/>
supervision of a physician.
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Store </content>at 20° to 25°C (68° to 77°F); excursions permitted between
  <br/>
15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR YOUR PROTECTION: </content>Do not use if blister is torn or broken.
 </paragraph>
                  <paragraph>The drug product contained in this package is from
  <br/>
NDC # 64380-971, Strides Pharma Inc.
 </paragraph>
                  <paragraph>Distributed by: American Health Packaging, Columbus, Ohio 43217</paragraph>
                  <paragraph>758201
  <br/>
0458201/0624
 </paragraph>
               </text>
               <effectiveTime value="20250204"/>
               <component>
                  <observationMedia ID="img_1d4dbee1-4b55-4ee9-e063-6394a90ad57b">
                     <text>10 mg Hydrocortisone Tablets Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="10 mg Hydrocortisone Tablets Carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_47690e7c-f1b4-4d05-8294-246a795b150d">
               <id root="2fb0b7eb-a087-d126-e063-6294a90a5c59"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel - Blister - 10 mg</title>
               <text>
                  <renderMultiMedia ID="id858" referencedObject="ID_60db5c08-d448-40a7-a59c-f0040cbcdeed"/>
                  <paragraph>Hydrocortisone 
  <br/>  Tablet, USP
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">10 mg</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250204"/>
               <component>
                  <observationMedia ID="ID_60db5c08-d448-40a7-a59c-f0040cbcdeed">
                     <text>10 mg Hydrocortisone Tablet Blister</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="10 mg Hydrocortisone Tablet Blister.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>